https://scientech-labs.com/FDA cGMP analytical testing lab supporting OTC drug, VMS, botanical, and cosmetic industrieso Partnered with Private Equity investors for due diligence, acquisition, and transition of Company from Founderso Implemented new structure and processes to increase productivity by 50%+ in first 6 monthso Developing new technology, capabilities and clients to grow revenue by 2x in 12 months

-- Conducted due diligence assessment for the acquisition of an analytical chemistry lab. Developed strategic growth plan for expansion of services, facilities, and business post-acquisition.-- Advised large Cannabis MSO on scientific strategy and structure for R&D, Breeding, and Product Development. Developed plan for efficient integration of assets and programs across several states.-- Initiated business development for a human genomics company seeking to develop corporate partnerships in the area of nutrigenomics. Engaged Fortune 100 companies in the food, beverage, and nutrition industries to pitch company and business opportunities.-- Advised CEOs of separation science and 3D-printing companies on intellectual property and business development strategies

Built an R&D team with responsibilities from Cannabis plant breeding to product development for Raw Garden. Directed strategy and operations for Breeding, Analytical Chemistry, Genomics, Data Science, Engineering, and Facilities. Devised the company's intellectual property strategy and partnered with external counsel to file 15+ patents.

Site leader for the Nutranext Business Unit's Global Innovation Center. Led scientific and product development efforts resulting in the introduction of over 50 dietary supplement products. Responsible for technology scouting and product innovations, ensuring safety of products, overseeing product development, and supporting a broad range of marketing and commercialization activities. Leading strategic planning, Stage Gate work processes, and new product ideation/evaluation for R&D. Managing clinical trials and development of label claims for Nutranext products. Nutranext was formerly known as Wellnext and was acquired by The Clorox Company in 2018. It comprises several Brands, including Rainbow Light, Natural Vitality, Neocell, and others.Vice President R&D - 2018-2020Director R&D - 2017

Developed knowledge of how natural products, phytonutrient diversity, and the microbiome alter the regulation of biological energy and influence performance in biological systems from microbes to Man. Translated this knowledge into business opportunities in the Industrial Biotechnology, Nutrition, and Pharmaceutical industries. BioElectron was formerly known as Edison Pharmaceuticals, Inc.

Working directly with the founders to plan business, financing, and technical strategy to launch Oak Therapeutics, Inc. Developed pitch decks for financing, proposals for grants, and material for technical presentations and investors.Oak Therapeutics has big goals - global health, dignity and sustainability. We change the way in which quality medicines are brought to people in need while being highly profitable. We reformulate existing pharmaceuticals and nutraceuticals using our proprietary drug delivery system, oral dissolvable film, and distribute them where they're needed most - regions where people die from diseases that have simple cures, such as diarrhea and malaria.

In charge of Strategic Planning, Intellectual Property (IP), and Licensing for Agricultural Biotechnology company focused on advanced biofuels. Reporting directly to the CEO, responsibilities included managing the intellectual property portfolio, technical strategic planning, grants and government relations, in/out-licensing, and defining the product development processes and pipeline to enable business and technical goals. Managed relationships with external counsel and participated in project management across the company to ensure linkage of strategic goals and daily operations. Coordinated submission of dozens of grant proposals to government agencies resulting in over $20M of funding for Ceres. Company liaison to DOE, USDA, USAID, ARPA-E, & BESC.Built and managed a plant biotechnology research team with a focus on engineering metabolic pathways in plants for pharmaceutical and nutrition product concepts. Served as technical manager, product development and business development leader for these business areas. Managed analytical chemistry platform for entire company (GC, LC, FT-NIR, GC-MS, LC-MS, LC-MSn).Senior Director, Technology Planning, Protection, and Acquisition (2011-2013).Director, Technology Planning, Protection, and Acquisition (2007-2010).Director, Natural Products Chemistry (2003-2006)

Created and managed a research group to support natural products research, bioanalytical chemistry (PK/ADME, stability, and formulation), sample archival, and analytical chemistry needs of discovery, preclinical, and clinical development programs. Conducted the technical due diligence assessment for the acquisition of Phytera, Inc. and coordinated the transfer and integration of physical, intellectual, and human assets into Galileo Labs.

Multiple positions in pharmaceutical and nutrition businesses. Monsanto Nutrition and Consumer Products SectorGroup Leader (2000) and Technical Leader (1999)Natural Products Chemistry. Discovery Process Coordinator. Led a group of scientists responsible for the creation and management of a natural products extract screening library and the isolation and identification of bioactive natural products from these sources for the development of nutrition and dietary supplement products. Established and managed collaborations and contracts with external academic, private, and government organizations to provide source materials for the screening libraries and other project needs. Assisted in project management and the design of the work processes for discovery research using high throughput screening (HTS) and LC-MS, LC-NMR, and other analytical techniques for the rapid isolation and identification of bioactive molecules.Searle Pharmaceutical R&DSenior Research Investigator (1994-98). Discovery research of natural products chemicals for pharmaceutical development. Integrated natural products research with high throughput screening (HTS). Developed structure-activity relationships (SAR) for lead structures (both synthetic and natural product chemicals). Interfaced with several research groups focused on the discovery of new molecular structures for the treatment of cancer and inflammatory, immunomodulatory, and infectious diseases via the inhibition of novel molecular targets.Monsanto Corporate ResearchSenior Research Chemist (1992-93). Isolated and identified natural products produced by plants, microorganisms, and marine organisms as leads for pharmaceutical development using state of the art chromatographic and spectroscopic techniques (HPLC and NMR). Initiated a program and established academic collaborations for the collection, extraction, screening, and isolation of natural products from marine organisms.